Trial reportThe Journal of pediatrics2017
Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
Trial report in The Journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH.The Journal of clinical endocrinology and metabolism · 2025Trial
- Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone.Human reproduction (Oxford, England) · 2020Trial
- Peripheral Precocious Puberty Due to Autonomous Gonadal Activation: A Multicenter Experience.Cureus · 2025Article
- Short Adult Height After Rapid-tempo Puberty: When is it too Late to Treat?Journal of clinical research in pediatric endocrinology · 2024Article
- Familial male-limited precocious puberty due to an activating mutation of the LHCGR: a case report and literature review.Annals of pediatric endocrinology & metabolism · 2024Article
- Sex non-specific growth charts and potential clinical implications in the care of transgender youth.Frontiers in endocrinology · 2023Article
- Familial Male-limited Precocious Puberty (FMPP) and Testicular Germ Cell Tumors.The Journal of clinical endocrinology and metabolism · 2022Review
- Precocious Puberty in a Boy With Bilateral Leydig Cell Tumors due to a Somatic Gain-of-FunctionJournal of the Endocrine Society · 2022Article
- Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.Frontiers in endocrinology · 2022Article
- Diagnosis and management of precocious sexual maturation: an updated review.European journal of pediatrics · 2021Review
- A Case of Familial Male-limited Precocious Puberty with a Novel MutationJournal of clinical research in pediatric endocrinology · 2021Article
- Should Skeletal Maturation Be Manipulated for Extra Height Gain?Frontiers in endocrinology · 2021Review
- Glycoprotein G-protein Coupled Receptors in Disease: Luteinizing Hormone Receptors and Follicle Stimulating Hormone Receptors.Diseases (Basel, Switzerland) · 2020Review
- [Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Article
- A Case of Familial Male-Limited Precocious Puberty in a Child With Klinefelter Syndrome.Journal of the Endocrine Society · 2018Article
- TESTOTOXICOSIS WITH AN EPISODIC COURSE: AN UNUSUAL CASE WITHIN A SERIES.AACE clinical case reportsArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveAntiandrogen, aromatase inhibitor, and gonadotropin-releasing hormone analog (GnRHa) treatment normalizes growth rate and bone maturation and increases predicted adult height (AH) in boys with familial male-limited precocious puberty (FMPP). To evaluate the effect of long-term antiandrogen, aromatase inhibitor, and GnRHa on AH, boys with FMPP who were treated were followed to AH. STUDY
designTwenty-eight boys with FMPP, referred to the National Institutes of Health, were started on antiandrogen and aromatase inhibitor at 4.9 ± 1.5 years of age; GnRHa was added at 6.9 ± 1.5 years of age. Treatment was discontinued at 12.2 ± 0.5 years of age (bone age, 14.4 ± 1.3). AH was assessed at 16.4 ± 1.3 years of age (bone age, 18.5 ± 0.6).
resultsAH (mean ± SD) for all treated subjects was 173.6 ± 6.8 cm (-0.4 ± 1.0 SD relative to adult US males). For 25 subjects with pretreatment predicted AH, AH significantly exceeded predicted AH at treatment onset (173.8 ± 6.9 vs 164.9 ± 10.7 cm; P < .001), but fell short of predicted AH at treatment discontinuation (177.3 ± 9.0 cm; P < .001). For 11 subjects with maternal or sporadic inheritance, the mean AH was 3.1 cm (0.4 SD score) below sex-adjusted midparental height (175.4 ± 5.8 vs 178.5 ± 3.1 cm [midparental height]; P = .10). For 16 subjects with affected and untreated fathers, AH was significantly greater than fathers' AH (172.8 ± 7.4 vs 168.8 ± 7.2 cm; P < .05).
conclusionsLong-term treatment with antiandrogen, aromatase inhibitor, and GnRHa in boys with FMPP results in AH modestly below sex-adjusted midparental height and within the range for adult males in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.